If a variant has more than one submission, it may be counted in more than one significance column. If this is the
case, the total number of variants will be less than the sum of the other cells.
pathogenic |
likely pathogenic |
uncertain significance |
likely benign |
benign |
protective |
risk factor |
not provided |
total |
25
|
21
|
112
|
1
|
1
|
5
|
1
|
993
|
1159
|
Gene and significance breakdown #
Total genes and gene combinations: 80
Gene or gene combination |
pathogenic |
likely pathogenic |
uncertain significance |
likely benign |
benign |
protective |
risk factor |
not provided |
total |
CFTR
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
371
|
371
|
BRCA1
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
225
|
225
|
BRCA2
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
180
|
180
|
CFTR, LOC111674472
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
44
|
44
|
BRCA1, LOC126862571
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
39
|
39
|
RBP3
|
1
|
0 |
38
|
0 |
0 |
0 |
0 |
0 |
39
|
MAN2B1
|
0 |
0 |
36
|
0 |
0 |
0 |
0 |
0 |
36
|
KCNQ1
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
28
|
28
|
ALB
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
19
|
19
|
KCNQ4
|
16
|
0 |
0 |
0 |
0 |
0 |
0 |
1
|
17
|
CFTR, LOC111674475
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
15
|
15
|
MYPN
|
0 |
2
|
13
|
0 |
0 |
0 |
0 |
0 |
15
|
PAX2
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
11
|
11
|
PRKAG3
|
0 |
0 |
10
|
0 |
0 |
0 |
0 |
0 |
10
|
CFTR, LOC113664106
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
7
|
7
|
ATP7B
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
6
|
6
|
ADAR
|
0 |
5
|
0 |
0 |
0 |
0 |
0 |
0 |
5
|
EGFR
|
0 |
0 |
5
|
0 |
0 |
0 |
0 |
0 |
5
|
APOC3
|
0 |
0 |
0 |
0 |
0 |
4
|
0 |
0 |
4
|
B3GALNT2
|
0 |
4
|
0 |
0 |
0 |
0 |
0 |
0 |
4
|
FAM111A
|
0 |
2
|
2
|
0 |
0 |
0 |
0 |
0 |
4
|
LOC129391064, MAN2B1
|
0 |
0 |
4
|
0 |
0 |
0 |
0 |
0 |
4
|
ADAR, LOC126805874
|
0 |
3
|
0 |
0 |
0 |
0 |
0 |
0 |
3
|
ACVRL1
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
2
|
2
|
CFTR, LOC111674477
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
2
|
2
|
EPB42
|
0 |
0 |
2
|
0 |
0 |
0 |
0 |
0 |
2
|
ESR1
|
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
2
|
HARS2
|
0 |
2
|
0 |
0 |
0 |
0 |
0 |
0 |
2
|
IGH, IGHM
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
2
|
2
|
KCNQ1, KCNQ1OT1
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
2
|
2
|
MECP2
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
2
|
2
|
PTPRQ
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
2
|
2
|
RHCE
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
2
|
2
|
SACS
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
2
|
2
|
ADD3
|
1
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
AQP2, AQP5
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
ARHGAP11A-SCG5, LOC125078054, SCG5
|
1
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
ATM, C11orf65
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
ATRX
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
CACNA1S
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
CFTR, LOC111674467
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
CNGA3
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
COL5A1
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
COL7A1
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
CSRP3
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
DYNC1H1
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
FAM111A, LOC130005740
|
0 |
1
|
0 |
0 |
0 |
0 |
0 |
0 |
1
|
FGFR2
|
1
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
GALC
|
0 |
0 |
1
|
0 |
0 |
0 |
0 |
0 |
1
|
GALT, IL11RA, LOC121331325, LOC130001682, LOC130001683, LOC130001684
|
1
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
GAN
|
0 |
0 |
0 |
0 |
1
|
0 |
0 |
0 |
1
|
GLRA1
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
HBB, LOC107133510, LOC110006319
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
HLA-B
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
HYCC1
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
KCNQ4, LOC129930282
|
1
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
KRAS
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
LOC130063648, MAN2B1
|
0 |
0 |
1
|
0 |
0 |
0 |
0 |
0 |
1
|
MED25
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
MMAB, MVK
|
0 |
0 |
0 |
1
|
0 |
0 |
0 |
0 |
1
|
MMP2
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
MYH11
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
NAGLU
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
NEFL
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
NOTCH3
|
1
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
PACS1
|
0 |
1
|
0 |
0 |
0 |
0 |
0 |
0 |
1
|
PAX8
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
PECAM1
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
PEX1
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
POU3F4
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
PTCH1
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
PYGM
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
SCN1A
|
1
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
SLC45A2
|
0 |
0 |
0 |
0 |
0 |
1
|
0 |
0 |
1
|
SPTLC2
|
1
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
STAT3
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
TMEM70
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
USB1
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
VWF
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
ZNF141
|
0 |
1
|
0 |
0 |
0 |
0 |
0 |
0 |
1
|
Condition and significance breakdown #
Condition |
pathogenic |
likely pathogenic |
uncertain significance |
likely benign |
benign |
protective |
risk factor |
not provided |
total |
Familial cancer of breast
|
0 |
0 |
0 |
0 |
0 |
0 |
1
|
444
|
445
|
Cystic fibrosis
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
440
|
440
|
Deficiency of alpha-mannosidase
|
0 |
0 |
41
|
0 |
0 |
0 |
0 |
0 |
41
|
Retinitis pigmentosa 66
|
1
|
0 |
38
|
0 |
0 |
0 |
0 |
0 |
39
|
not provided
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
27
|
27
|
Long QT syndrome 1
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
26
|
26
|
Autosomal dominant nonsyndromic hearing loss 2A
|
17
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
17
|
Dilated cardiomyopathy 1KK
|
0 |
2
|
13
|
0 |
0 |
0 |
0 |
0 |
15
|
Alloalbuminemia
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
10
|
10
|
Increased muscle glycogen content
|
0 |
0 |
10
|
0 |
0 |
0 |
0 |
0 |
10
|
Analbuminemia
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
9
|
9
|
Aicardi-Goutieres syndrome 6
|
0 |
8
|
0 |
0 |
0 |
0 |
0 |
0 |
8
|
Wilson disease
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
6
|
6
|
Lung carcinoma
|
0 |
0 |
5
|
0 |
0 |
0 |
0 |
0 |
5
|
Coronary heart disease
|
0 |
0 |
0 |
0 |
0 |
4
|
0 |
0 |
4
|
Jervell and Lange-Nielsen syndrome 1
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
4
|
4
|
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 11
|
0 |
4
|
0 |
0 |
0 |
0 |
0 |
0 |
4
|
Osteocraniostenosis
|
0 |
3
|
0 |
0 |
0 |
0 |
0 |
0 |
3
|
Autosomal dominant Kenny-Caffey syndrome
|
0 |
0 |
2
|
0 |
0 |
0 |
0 |
0 |
2
|
Autosomal recessive agammaglobulinemia 1
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
2
|
2
|
Autosomal recessive nonsyndromic hearing loss 84A
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
2
|
2
|
Hereditary spherocytosis type 5
|
0 |
0 |
2
|
0 |
0 |
0 |
0 |
0 |
2
|
Perrault syndrome 2
|
0 |
2
|
0 |
0 |
0 |
0 |
0 |
0 |
2
|
Telangiectasia, hereditary hemorrhagic, type 2
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
2
|
2
|
Achromatopsia 2
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
Allopurinol response
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
Alpha thalassemia-X-linked intellectual disability syndrome
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
Aortic aneurysm, familial thoracic 4
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
Ataxia-telangiectasia syndrome
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
Cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1
|
1
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
Cerebral palsy
|
1
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
Charcot-Marie-Tooth disease
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
Charcot-Marie-Tooth disease axonal type 2V
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
Charcot-Marie-Tooth disease type 2B2
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
Charcot-Marie-Tooth disease type 2E
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase
|
1
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
Dominant dystrophic epidermolysis bullosa with absence of skin
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
Ehlers-Danlos syndrome, classic type, 1
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
Estrogen resistance syndrome
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
Galactosylceramide beta-galactosidase deficiency
|
0 |
0 |
1
|
0 |
0 |
0 |
0 |
0 |
1
|
Giant axonal neuropathy 1
|
0 |
0 |
0 |
0 |
1
|
0 |
0 |
0 |
1
|
Glycogen storage disease, type V
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
Gorlin syndrome
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
Hyperekplexia 1
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
Hypertrophic cardiomyopathy 12
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
Hypomyelination and Congenital Cataract
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
Leber congenital amaurosis
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
Malignant melanoma of skin
|
0 |
0 |
0 |
0 |
0 |
1
|
0 |
0 |
1
|
Methylmalonic aciduria, cblB type
|
0 |
0 |
0 |
1
|
0 |
0 |
0 |
0 |
1
|
Neuropathy, hereditary sensory and autonomic, type 1C
|
1
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
Noonan syndrome 1
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
Pfeiffer syndrome
|
1
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
Poikiloderma with neutropenia
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
Polydactyly, postaxial, type A6
|
0 |
1
|
0 |
0 |
0 |
0 |
0 |
0 |
1
|
Polyposis syndrome, hereditary mixed, 1
|
1
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
Schuurs-Hoeijmakers syndrome
|
0 |
1
|
0 |
0 |
0 |
0 |
0 |
0 |
1
|
Severe myoclonic epilepsy in infancy
|
1
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
X-linked mixed hearing loss with perilymphatic gusher
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
1
|
The information on this website is not intended for direct
diagnostic use or medical decision-making without review by a
genetics professional. Individuals should not change their
health behavior solely on the basis of information contained on
this website. Neither the University of Utah nor the National
Institutes of Health independently verfies the submitted
information. If you have questions about the information
contained on this website, please see a health care
professional.